Alx Oncology Holdings INC Form 4 insider transactions

Director Alan B. Sandler reports the acquisition of stock options in ALX Oncology Holdings Inc.

Jaume Pons, President & CSO of ALX Oncology Holdings Inc., exercised stock options and sold shares on July 11, 2024, according to a recent SEC filing.

Shelly Pinto, SVP, Finance and CAO of ALX Oncology Holdings Inc, reports the sale of 1,823 shares of common stock to cover tax obligations related to vesting restricted stock units.

Shelly Pinto, SVP, Finance and CAO of ALX Oncology Holdings Inc., sold 1,373 shares of common stock on July 1, 2024, to satisfy tax obligations related to vesting restricted stock units.

Sophia Randolph, Chief Medical Officer of ALX Oncology Holdings Inc., sold 3,273 shares of common stock on July 1, 2024, to satisfy tax obligations related to vesting restricted stock units.

Jaume Pons, President & CSO of ALX Oncology Holdings Inc., sold 10,758 shares of common stock on July 1, 2024, to satisfy tax obligations related to vesting restricted stock units.

Peter Garcia, CFO of ALX Oncology Holdings Inc., reports the disposal of shares to cover tax obligations and acquisition of shares through the employee stock purchase plan.

ALX Oncology's CFO, Peter Garcia, files an amended Form 4 disclosing a purchase of 12,000 shares and a subsequent agreement to reimburse the company for profits from a short-swing transaction.

Peter Garcia, CFO of ALX Oncology Holdings Inc, recently purchased 12,000 shares of ALXO common stock at an average price of $8.5282.

Director Rekha Hemrajani acquired 20,200 stock options in ALX Oncology Holdings Inc. on June 13, 2024.

Director J. Scott Garland acquired stock options for 20,200 shares of ALX Oncology Holdings Inc on June 13, 2024.

Director Corey S. Goodman acquired stock options in ALX Oncology Holdings Inc. on June 13, 2024.

Jaume Pons, President & CSO of ALX Oncology Holdings Inc., exercised stock options and sold 20,000 shares of common stock on June 4, 2024.

Sophia Randolph, Chief Medical Officer of ALX Oncology Holdings Inc., sold shares of common stock on May 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Jaume Pons, President & CSO of ALX Oncology Holdings Inc, exercised stock options and sold 20,000 shares of common stock at a weighted average price of $15.9167 on May 6, 2024, under a pre-arranged 10b5-1 trading plan.

Jaume Pons, President & CSO and Director of ALX Oncology Holdings Inc., exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Jaume Pons, President & CSO and Director of ALX Oncology Holdings Inc., sold 20,000 shares of common stock on April 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

ALX Oncology's CEO, Jason Lettmann, recently purchased 4,400 shares of the company's common stock at a price of $11.3117 per share.